Welcome to our dedicated page for Scinai Immunotherapeutics Ltd. SEC filings (Ticker: SCNI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) files its regulatory reports as a foreign private issuer with the U.S. Securities and Exchange Commission, primarily through annual reports on Form 20‑F and current reports on Form 6‑K. This page provides access to those SEC filings, along with AI-assisted tools that help explain their contents in clear language.
In its 20‑F annual report, Scinai presents audited financial statements, a description of its dual business model in I&I biologics and CDMO services, risk factors, and details on capital structure and governance. The company’s 6‑K filings furnish interim information such as quarterly and half‑year financial results, business updates on Scinai Bioservices and the I&I pipeline, grant awards, and material agreements, including Standby Equity Purchase Agreements with Yorkville Advisors.
Recent 6‑Ks also describe grant applications and decisions related to programs like PC111, a human anti‑Fas Ligand monoclonal antibody in development via an option to acquire Pincell Srl, and governance matters such as changes in board composition and independent registered public accounting firms as part of cost-cutting measures. Other 6‑Ks incorporate press releases on Israel Innovation Authority funding for an advanced fill‑and‑finish system and business updates for the first half of 2025.
On Stock Titan, investors can review these filings in chronological order and use AI-powered summaries to quickly understand key points in lengthy documents. The platform highlights important elements in Scinai’s filings, such as financing arrangements, grant-related disclosures, and updates on its I&I and CDMO operations, helping readers navigate complex regulatory language without replacing the full text of the original SEC documents.
Scinai Immunotherapeutics Ltd. scheduled its Annual General Meeting of Shareholders for December 22, 2025 at 11:00 a.m. Israel time at Goldfarb Gross Seligman & Co., One Azrieli Center, Round Tower, Tel Aviv.
The company furnished a Notice and Proxy Statement as Exhibit 99.1 and a Proxy Card as Exhibit 99.2. This report is incorporated by reference into the company’s Registration Statements on Forms S-8 (File Nos. 333-271293, 333-239344) and F-3 (File Nos. 333-274078, 333-276767).
Scinai Immunotherapeutics reported governance and audit changes linked to cost-cutting. Prof. Avner Rotman and Dr. Morris Laster tendered resignations as directors, effective December 31, 2025, at the request of the Chairman and after consultation with major shareholders.
The Audit Committee recommended appointing Ziv Haft as independent registered public accounting firm for the fiscal year ending December 31, 2025 and until the next annual meeting, subject to shareholder approval. PwC’s engagement will conclude at the upcoming meeting. The company noted no disagreements and no reportable events with PwC for 2023 and 2024.
Scinai Immunotherapeutics Ltd. filed a Form S-8 to register an additional 4,000,000,000 ordinary shares, no par value, deposited as American Depositary Shares represented by ADRs, for issuance under the Company’s 2018 Israeli Share Option Plan.
This filing adds capacity for equity compensation grants under the plan. The document incorporates by reference the Company’s future Exchange Act reports and includes standard undertakings, exhibit references, and Israeli law indemnification provisions for directors and officers.
Scinai Immunotherapeutics Ltd. filed a Form 6-K describing a new grant award from the Israel Innovation Authority. The grant is intended to support expansion of the company’s fill-and-finish capabilities as a contract development and manufacturing organization (CDMO), which are services used by biopharma companies to prepare and package biological products.
The company reports that it issued a press release about this grant on October 6, 2025, which is attached as an exhibit to the filing. Scinai also states that this Form 6-K, with limited exceptions, is incorporated by reference into its existing registration statements on Form S-8 and Form F-3, meaning the disclosed information becomes part of those previously filed securities registration documents.
Scinai Immunotherapeutics Ltd. (SCNI) Schedule 13G/A reports that Daniel E. Stone and RK Stone Miami, LLC disclosed beneficial ownership in the issuer's American Depositary Shares, each representing 4,000 ordinary shares. Daniel E. Stone reports 346,667 ADSs (9.9%) and RK Stone Miami, LLC reports 282,467 ADSs (8.1%). The filing notes RK holds a mix of directly held ADSs and ADSs issuable upon exercise of pre-funded warrants and that exercise is limited to avoid beneficial ownership above 9.99%. The filers certify the holdings were not acquired to influence control.
FAQ
What is the current stock price of Scinai Immunotherapeutics Ltd. (SCNI)?
What is the market cap of Scinai Immunotherapeutics Ltd. (SCNI)?
